Controlling the ‘social life’ of proteins aims to transform drug discovery
A new £3.4 million programme will develop new tools to understand which interactions between proteins in the human body are relevant to disease. Currently, only a handful of drugs in clinical use work by targeting protein-protein interactions. The new project, which will launch on 1 February, 2016, will involve researchers from the University of Leeds, the University of Bristol and three drug discovery organisations: the Northern Institute for Cancer Research, Newcastle University; AstraZeneca; and Domainex.
